Autolus Therapeutics (AUTL) Interest Coverage Ratio (2021 - 2026)
Autolus Therapeutics' (AUTL) quarterly Interest Coverage Ratio came in at 3.17 in Q4 2025, down 228.98% YoY from 2.46 in Q4 2024, and down 425.97% on a QoQ basis from 0.6 in Q3 2025.
Powered by 
Analysis
Autolus Therapeutics (AUTL) Interest Coverage Ratio (2021 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 8 years of Interest Coverage Ratio data on file, last reported at 3.17 in Q4 2025.
- Quarterly Interest Coverage Ratio fell 228.98% year-over-year to 3.17 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 21.04 (up 19.02% YoY) and the FY2025 annual result came in at 1.09, up 29.07% from the prior year.
- Interest Coverage Ratio slipped to 3.17 in Q4 2025, from 0.6 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 2.46 in Q4 2024 to a low of 325.35 in Q4 2021.
- A 5-year average of 26.28 and a median of 6.07 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio jumped 239.15% — and 2025, when it tumbled 228.98%.
- Tracing AUTL's Interest Coverage Ratio over 5 years: stood at 325.35 in 2021, then surged by 98.96% to 3.37 in 2022, then surged by 47.53% to 1.77 in 2023, then soared by 239.15% to 2.46 in 2024, then plunged by 228.98% to 3.17 in 2025.
- The last three Interest Coverage Ratio figures came in at 3.17 (Q4 2025), 0.6 (Q3 2025), and 0.51 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Autolus Therapeutics | 594.86 Mn | 393.23 Mn | 25.22 Mn | 16.39 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 16.39 |
| Dec 31, 2025 | -3.17 |
| Sep 30, 2025 | -6.81 |
| Jun 30, 2025 | 8.96 |
| Mar 31, 2025 | -6.43 |
| Dec 31, 2024 | 2.46 |
| Sep 30, 2024 | -6.35 |
| Jun 30, 2024 | -5.79 |
| Mar 31, 2024 | -2.01 |
| Dec 31, 2023 | -1.77 |
| Sep 30, 2023 | -8.56 |
| Jun 30, 2023 | -8.84 |
| Mar 31, 2023 | -7.98 |
| Dec 31, 2022 | -3.37 |
| Sep 30, 2022 | -20.19 |
| Jun 30, 2022 | -21.58 |
| Mar 31, 2022 | -20.22 |
| Dec 31, 2021 | -20.90 |